Bank of China Securities released a research report on April 8 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) Achieving net profit of 619 million yuan to mother, a year-on-year decrease of 6.55%, putting pressure on the profit side. The company adjusted its drug sales model in 2023, and its main business maintained a growth trend, while vigorously promoting R&D investment and deepening treatment fields such as neuropsychiatry; 2) the company achieved steady growth on the revenue side in 2023, and the profit side was under slight pressure; 3) the sales structure of finished drugs was adjusted to further expand incremental space; 4) R&D investment increased, and the pipeline is expected to continue to advance. (Mainichi Keizai Shimbun)
中银证券4月8日发布研报称，给予京新药业（002020.SZ）买入评级。评级理由主要包括：1）实现归母净利润6.19亿元，同比下降6.55%，利润端有所承压。公司2023年实现药品销售模式调整，主营业务保持增长态势，同时大力推进研发投入，深耕精神神经等优势治疗领域；2）公司2023年收入端实现稳健增长，利润端略有承压；3）成品药销售架构调整，进一步实现增量空间拓展；4）研发费用投入加大，管线有望持续推进。（每日经济新闻）
Bank of China Securities released a research report on April 8 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating. The main reasons for the rating include: 1) Achieving net profit of 619 million yuan to mother, a year-on-year decrea
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.